Company code: Hunan Warrant Pharmaceutical Co.Ltd(688799) company abbreviation: Hunan Warrant Pharmaceutical Co.Ltd(688799) Announcement No.: 2022013 Hunan Warrant Pharmaceutical Co.Ltd(688799) 2021 annual report summary
Section I important tips
1 the summary of this annual report comes from the full text of the annual report. In order to fully understand the company’s operating results, financial status and future development plan, investors should http://www.sse.com.cn./ The website carefully reads the full text of the annual report. 2 major risk tips
Please refer to “section III Management Discussion and analysis” of the company’s 2021 annual report.
3 the board of directors, the board of supervisors and the directors, supervisors and senior managers of the company guarantee the authenticity, accuracy and completeness of the contents of the annual report, and there are no false records, misleading statements or major omissions, and bear individual and joint legal liabilities. 4. All directors of the company attended the board meeting. 5. Tianjian Certified Public Accountants (special general partnership) issued a standard unqualified audit report for the company. 6. The company is not profitable and has not yet achieved profitability when it is listed □ yes √ No 7. The profit distribution plan or the plan for the conversion of provident fund into share capital in the reporting period adopted by the resolution of the board of directors
Audited by Tianjian Certified Public Accountants (special general partnership), the company realized the net profit attributable to the parent company of RMB 16076074100 and the net profit of the parent company of RMB 11001930634 in 2021; As of December 31, 2021, the profit available for distribution of the parent company was RMB 42779720620. According to the deliberation and approval of the third meeting of the third board of directors of the company, the company plans to distribute cash dividends of RMB 7.00 (including tax) to all shareholders for every 10 shares in 2021. As of December 31, 2021, the total share capital of the company is 93800000 shares. Based on this calculation, the total cash dividend to be distributed is RMB 656 Shanghai Pudong Development Bank Co.Ltd(600000) 0 (including tax). The total cash dividends of the company in this year accounted for 40.84% of the net profit attributable to the parent company in this year. If the total share capital of the company changes from the date of disclosure of this announcement to the date of equity distribution and equity registration, the company plans to maintain the total distribution unchanged and adjust the distribution proportion per share accordingly. In case of subsequent changes in the total share capital, the specific adjustment will be announced separately.
The profit distribution plan has been approved by the board of supervisors after the independent directors issued their independent opinions. The profit distribution plan still needs to be reviewed by the company’s 2021 annual general meeting of shareholders. 8. Whether there are important matters such as special arrangements for corporate governance □ applicable √ not applicable
Section II basic information of the company
1、 Company profile company stock profile √ applicable □ not applicable
Company stock profile
Stock type stock exchange and sector stock abbreviation stock abbreviation before stock code change
RMB ordinary shares (A shares) Shanghai Stock Exchange Kechuang board Hunan Warrant Pharmaceutical Co.Ltd(688799) Hunan Warrant Pharmaceutical Co.Ltd(688799) /
Profile of the company’s depositary receipts □ applicable √ not applicable contact person and contact information
Contact person and contact information secretary of the board of directors (domestic representative of information disclosure) securities affairs representative
Name Dou linqiao Bridge
Office address: building C7, No. 28, Lutian Road, Yuelu District, Changsha City
Tel: 073185910599073185910599
E-mail [email protected]. [email protected].
2、 Introduction to the company’s main business during the reporting period (I) main business, main products or services 1 Main business
The company is a high-tech enterprise mainly engaged in the R & D, production and sales of chemical raw materials, chemical pharmaceutical preparations and traditional Chinese medicine preparations. Since its establishment, the company has focused exclusively on the expansion of its main business, and gradually built a R & D system from new product project approval, research, registration to industrialization, three production bases characterized by chemical APIs, chemical pharmaceutical preparations, plant extraction raw materials and Chinese patent medicines, as well as a marketing network that can widely cover grade hospitals, grass-roots medical institutions and OTC terminals; It has formed two complete industrial chains from chemical raw materials to chemical preparations, from traditional Chinese medicine pretreatment, extraction and separation to Chinese patent medicine. The internal cooperation and supporting capacity of R & D and industrialization have been continuously strengthened, and the company’s operating revenue and profit have maintained rapid and stable growth. At the same time, with the comprehensive ability developed by the main business expansion, the company cultivates and develops the professional platform and professional team of CMO / cdmo, and provides comprehensive CMO / cdmo business services from small-scale test to pilot test and production verification for R & D institutions and drug holder institutions. 2. Main products (1) preparation products
After years of development, as of the disclosure date of this report, the company has obtained 39 registration approvals for chemical pharmaceutical preparations and 21 registration approvals for traditional Chinese medicine preparations. Its products cover key treatment fields such as digestion, respiration, anti infection and children’s medication. The main products of the company are as follows:
Indications or functions of main products in the treatment field
Colloidal pectin bismuth dry suspension is suitable for the treatment of peptic ulcer, especially Helicobacter pylori related ulcer, as well as chronic superficial and atrophic gastritis.
Colloidal pectin bismuth capsule in the field of digestion is suitable for the treatment of peptic ulcer, especially Helicobacter pylori related ulcer. It can also be used for chronic superficial and atrophic gastritis.
Bismuth potassium citrate capsule is used for chronic gastritis and relieving stomach pain, heartburn (heartburn) and acid reflux caused by excessive gastric acid.
Indications or functions of main products in the treatment field
It is suitable for the treatment of peptic ulcer, especially Helicobacter pylori related colloidal bismuth tartrate capsule ulcer; It can also be used for chronic colitis, diarrhea caused by ulcerative colitis and chronic superficial and atrophic gastritis.
Docetaxel sodium tablets are used for chronic functional constipation.
Montmorillonite powder is used for acute and chronic diarrhea in adults and children.
Jianwei Xiaoshi tablet is mainly used to treat food accumulation caused by weakness of the spleen and stomach, symptoms, lack of diet, belching, sour and smelly, abdominal distension and fullness; Dyspepsia with the above symptoms.
Pantoprazole sodium enteric coated tablets are used for active peptic ulcer (gastric and duodenal ulcer), reflux esophagitis and Zhuo AI syndrome.
Pantoprazole sodium enteric coated capsule is used for active peptic ulcer (gastric and duodenal ulcer), reflux esophagitis and Zhuo AI syndrome.
Lansoprazole enteric coated tablets are used for gastric and duodenal ulcer, reflux esophagitis and Zhuo AI syndrome.
Polyethylene glycol 4000 powder is used to treat the symptoms of constipation in adults and children over 8 years old (including 8 years old).
Treat respiratory diseases with too much thick mucus secretion, such as tracheitis with acetylcysteine solution inhaled in the field of acute bronchitis, chronic bronchitis and its deterioration, emphysema, mucus obstruction and bronchiectasis.
1. This product is used to treat the following infections caused by sensitive Escherichia coli, Enterococcus faecalis, Klebsiella pneumoniae, Citrobacter, enterobacter, phosphonomycin mirabilis and aminobutanol scattered bacilli: 1) acute simple urinary tract infection. 2) Asymptomatic bacteriuria. 2. This product is used to prevent infection caused by surgery or lower urinary tract diagnosis (e.g. transurethral resection).
Naked flower Zizhu dispersible tablet has the functions of anti-inflammatory, detoxification, astringency and hemostasis. For inflammation caused by bacterial infection, acute infectious hepatitis, respiratory and gastrointestinal bleeding.
Clotrimazole vaginal tablets are used for candidal vulvovaginosis.
This product is applicable to the anti infection fields of Staphylococcus and Streptococcus sensitive to faropenem (including Staphylococcus, Streptococcus pneumoniae, Enterococcus, Moraxella catarrhalis, drugs for adults and children), enterobacter, Citrobacter, Klebsiella, enterobacter, qifaropenem Sodium Granule isoproterenous, Haemophilus influenzae, digestive Streptococcus Treatment of infectious diseases caused by Bacteroides, bacterias, and Propionibacterium acnes.
It is applicable to the treatment of chronic adult hepatitis B (including patients with compensatory and decompensated liver diseases) with active virus replication, continuous increase of serum transaminase (ALT) or active liver histology. Entecavir granules are also suitable for the treatment of nucleoside naive children aged 2 to 18 years with chronic HBV infection compensated liver disease. There is evidence of active virus replication and continuous increase of serum ALT level or histological evidence of moderate to severe inflammation and / or fibrosis.
In other therapeutic fields, Ferrous Succinate Tablets are used for the prevention and treatment of iron deficiency anemia.
Indications or functions of main products in the treatment field
Diclofenac sodium sustained release tablets can alleviate the swelling and pain of rheumatoid arthritis and osteoarthritis, and various soft tissue rheumatic pain
Metformin Hydrochloride and Glipizide Tablets is used for the initial treatment of type II diabetes, and it is used to improve type II diabetes without diet and exercise therapy.
Stable angina pectoris (chronic angina pectoris); Vasospasm nifedipine sustained release tablets angina pectoris (Prinzmetal’s angina pectoris, variant angina pectoris);
